Tyrosinase mRNA in Blood of Patients With Melanoma Treated With Adjuvant Interferon

Mellado, Begoña; Vela, María; Colomer, Dolors; Gutiérrez, Lorena; Castel, Teresa; Quintó, Llorenç; Fontanillas, Montserrat; Reguart, Noemı́; Domingo-Domenech, J.; Montagut, Clara; Vila, Jordi; Gascón, Pedro

doi:10.1200/jco.2002.08.009

Cited by 53 publications

(48 citation statements)

References 24 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the majority of them developed evidence of circulating melanoma cells during follow-up, whereas only 13 (12%) had positive baseline determinations. Mellado et al (2002) reported similar results in a cohort of 50 stage III patients treated with adjuvant IFN, showing positive results in 12% before treatment and 46% during follow-up. On the other hand, Gogas et al (2002) found a higher percentage of positive results before treatment (50%) in 60 stage IIB -III disease-free patients.…”

Section: Discussionsupporting

confidence: 58%

“…It is not conceivable to associate a metastatic spreading with a positive tyrosinase finding detected more than 1 year before, as all the relapses in positive patients from our series occurred within 6 months from the last positive determination. The conversion from a positive to one or more negative determinations during follow-up could be a consequence of adjuvant treatment, as suggested by Mellado et al (2002). Also in our experience, all the positive patients not yet relapsed became negative while under adjuvant treatment.…”

Section: Discussionsupporting

confidence: 58%

“…The meta-analysis performed by Tsao et al (2001) suggests that, at the present time, RT -PCR for tyrosinase mRNA is of limited value given the unreliability of the procedure and the lack of data on the outcome of stage I -III positive patients. More recently, Mellado et al (2002) and Gogas et al (2002) showed that the detection of tyrosinase mRNA in disease-free melanoma patients treated with adjuvant interferon (IFN) is associated with an increased risk of relapse and shorter disease-free survival (DFS).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients

et al. 2003

View full text Add to dashboard Cite

The aim of this study is to define the relationship between the tyrosinase expression in the peripheral blood and the clinical course of the disease in stage III disease-free melanoma patients after radical lymph node dissection. RT -PCR techniques were used to identify tyrosinase mRNA in 110 patients; a total of 542 blood samples were investigated. In all, 54 patients (49%) showed at least one positive result; 13 patients (11.8%) showed baseline positive results: six became negative thereafter, whereas seven showed follow-up positive results until disease progression occurred. One or more positive determinations were found during follow-up in 41 patients with negative baseline tyrosinase. No correlation was found between baseline results and the relapse rate or disease-free survival (DFS), whereas a significant correlation was found between positive tyrosinase results and disease recurrence during follow-up. In fact, 72.9% of positive patients relapsed, but only 19.3% of negative cases did so. The median interval between the positive results and the clinical demonstration of the relapse was 1.9 months (range 1 -6.6). Disease-free survival multivariate analysis selected, as independent variables, Breslow thickness (P ¼ 0.05), lymph node involvement according to the AJCC classification (P ¼ 0.05) and tyrosinase expression (P ¼ 0.0001). In conclusion, RT -PCR tyrosinase mRNA expression is a reliable and reproducible marker associated with a high risk of melanoma progression and we encourage its clinical use in routine follow-up.

show abstract

Section: Discussionsupporting

confidence: 58%

Section: Discussionsupporting

confidence: 58%

mentioning

confidence: 99%

See 1 more Smart Citation

Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients

et al. 2003

View full text Add to dashboard Cite

show abstract

“…67,68 Patients with circulating tumor cells have been shown to have inferior survival, 69 but some investigators have found that circulating melanoma cells add little prognostic value beyond that defined by disease stage. 70 If present in circulation, the tumor cells are usually in extremely minute concentrations.…”

Section: Future Directionsmentioning

confidence: 99%

Circulating Serologic and Molecular Biomarkers in Malignant Melanoma

Palmer

Erickson

Ichetovkin³

et al. 2011

Mayo Clinic Proceedings

View full text Add to dashboard Cite

“…The detection of circulating melanoma cell has been proposed as a sensitive method for selecting patients who are in a high risk to relapse. 1,2 However, after the original description of molecular monitoring of circulating melanoma cells by reverse transcriptase-PCR (RT-PCR) had been published, 3 inconsistent data on sensitivity and clinical relevance of this method have been reported [4][5][6][7][8][9][10][11][12][13][14][15] . Two possible reasons for the conflicting results may exist: (a) a single marker detection, (b) conventional or semiquantitative RT-PCR assay.…”

Section: Introductionmentioning

confidence: 99%

Early Detection of Melanoma Progression by Quantitative Real-time RT-PCR Analysis for Multiple Melanoma Markers

2008

View full text Add to dashboard Cite

Standard screening of melanoma patients is a useful tool for predicting outcome of patients, however, an instant methodology for exact detection of subclinical disease or monitoring treatment response is under investigation.Detection of circulating melanoma cells is, therefore, a possible novel promising staging method. However, inconsistent data on method sensitivity and on the predicted patient outcome has been shown repeatedly.Recently, a multimarker real-time RT-PCR methodology for quantification of five melanoma markers Melan-A, gp 100, MAGE-3, MIA and tyrosinase was described by our group. In the current prospective trial, blood specimens of 65 patients with AJCC stage IIB-III cutaneous melanoma after surgery were periodically examined. In the above group, 27 % of subjects relapsed during the study. Prior to the disease progression we could observe a statistically significant tumor marker elevation in previous 0 to 9 months in all patients with clinical relapse. MAGE-3 became the most sensitive progression marker. During progression, three concordant positive markers were seen in 39 % of patients, followed by two concordant positive markers in 28 % and 1 marker in 33 %.This study supports the use of a multimarker real-time RT-PCR as a disease progression predictor. The dynamic assessment of serially obtained blood specimens represents a useful method for early metastasis detection and treatment response of melanoma patients. (Keio J Med 57 (1) : 57 -64, March 2008)

show abstract

Tyrosinase mRNA in Blood of Patients With Melanoma Treated With Adjuvant Interferon

Cited by 53 publications

References 24 publications

Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients

Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients

Circulating Serologic and Molecular Biomarkers in Malignant Melanoma

Early Detection of Melanoma Progression by Quantitative Real-time RT-PCR Analysis for Multiple Melanoma Markers

Contact Info

Product

Resources

About